vimarsana.com
Home
Live Updates
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors : vimarsana.com
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors : vimarsana.com
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors
HANGZHOU, China--(BUSINESS WIRE)--Jan 8, 2024--
Related Keywords
Hangzhou ,
Zhejiang ,
China ,
Dan Eramian ,
Donald Wyatt ,
Yuhong Xu ,
Business Development Contact ,
Opus Biotech Communications ,
Field Biopharmaceuticals ,
Media Contact ,
Development Contact ,
Business Wire ,
Nation World ,
Egion ,